Antibiotic resistance, and, in a broader perspective, antimicrobial resistance (AMR),
continues to evolve and spread beyond all boundaries. As a result, infectious diseases have …

Monoclonal antibodies (mAbs) have become one of the most important classes of
biopharmaceutical products, and they continue to dominate the universe of …

Standard cancer therapies sometimes fail to deliver chemotherapeutic drugs to tumor cells
in a safe and effective manner. Nanotechnology takes the lead in providing new therapeutic …

Highlights•Phages use structurally diverse receptor binding proteins (RBPs) to target
different cell wall structures.•RBPs play a critical role in spatial and temporal positioning of …

Oral inhalation is the preferred route for delivery of small molecules to the lungs, because
high tissue levels can be achieved shortly after application. Biologics are mainly …

Nanoparticles (NPs) are promising drug delivery systems (DDS) for identifying and treating
cancer. Active targeting NPs can be generated by conjugation with ligands that bind …

Monoclonal antibodies have evolved from research tools to powerful therapeutics in the past
30 years. Clinical success rates of antibodies have exceeded expectations, resulting in …

Chemiluminescence immunoassay (CLIA) has been greatly developed in the past several
decades due to its good sensitivity and specificity. Nowadays, CLIA has been highly …

Passive and active targeted nanoparticulate delivery systems show promise to compensate
for lacking properties of conventional therapy such as side effects, insufficient efficiency and …

Molecular targeted therapy of cancer has always been the focus of clinicians. Among those
therapeutic targets, the human epidermal growth factor receptor-2 (HER-2) signaling …